1 Min Read
(Reuters) - Pacira Pharmaceuticals Inc said its lead drug did not meet the main goal in a late-stage trial of reducing pain for patients undergoing a surgical procedure called posterolateral thoracotomy.
Pacira said the company did not meet the main goal of reducing pain scores over 72 hours, compared with a placebo.
The results are from a second late-stage study of the drug, Exparel, which is already approved as a single-dose injection to treat postsurgical pain.
Reporting By Vrinda Manocha in Bangalore; Editing by Maju Samuel